Status:
ACTIVE_NOT_RECRUITING
Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Acute Myocardial Infarction (AMI)
Left Ventricular Remodeling
Eligibility:
All Genders
18+ years
Brief Summary
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to in...
Detailed Description
Despite advances in AMI treatment, a substantial proportion of patients develop LVAR, leading to heart failure and increased MACE risk. Conventional biomarkers (e.g., troponin, NT-proBNP) lack suffici...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
- Willingness to provide informed consent.
Exclusion
- Prior surgery or trauma.
- Renal failure with glomerular filtration \<30 ml/min.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06885619
Start Date
January 1 2025
End Date
December 31 2027
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital, Capital Medical University.
Beijing, Beijing Municipality, China, 100029